Development of covalent antagonists for β1- and β2-adrenergic receptors.

Development of covalent antagonists for β1- and β2-adrenergic receptors.
复制标题

β1-和β2-肾上腺素能受体共价拮抗剂的开发

DOI:
10.1016/j.bmc.2019.05.034
复制
发表时间:
2019
影响因子:
3.5
通讯作者:
P. Gmeiner
P. Gmeiner
中科院分区:
医学3区
文献类型:
--
作者:
T. Schwalbe;H. Hübner;P. Gmeiner

文献摘要

参考文献

被引文献

相似文献

配体与特定GPCR结合位点的选择性共价连接在结构生物学、分子药理学和药物设计中引起了相当大的兴趣。我们最近报道了一种共价结合的去甲肾上腺素类似物(FAUC 37),其促进处于活性状态的β2-肾上腺素能受体(β2ARH2.64C)的结晶。本文报道了基于肾上腺素能β1和β 2受体拮抗剂药效团的共价结合二硫键配体的立体专一性合成。放射性配体耗竭实验表明,二硫键功能化的配体能够与受体突变体β 1ARI2.64C和β2ARH2.64C的特定半胱氨酸残基快速形成共价键。普萘洛尔衍生物(S)-1在30分钟内几乎完全不可逆地阻断β 2ARH2.64C。基于CGP 20712 A的配体(S)-4显示出非常低浓度的β2ARH2.64Cat的有效共价阻断。类似物(S)-5在β 1ARI2.64C和β 2ARH2.64C突变体上表现出非凡的共价交联,同时保留了对β1AR野生型的41倍于β2AR的选择性。这些化合物可作为研究β1/β 2亚型选择性或研究GPCR运输和二聚化的有价值的分子工具。
The selective covalent tethering of ligands to a specific GPCR binding site has attracted considerable interest in structural biology, molecular pharmacology and drug design. We recently reported on a covalently binding noradrenaline analog (FAUC37) facilitating crystallization of the β2-adrenergic receptor (β2ARH2.64C) in an active state. We herein present the stereospecific synthesis of covalently binding disulfide ligands based on the pharmacophores of adrenergic β1- and β2receptor antagonists. Radioligand depletion experiments revealed that the disulfide-functionalized ligands were able to rapidly form a covalent bond with a specific cysteine residue of the receptor mutants β1ARI2.64Cand β2ARH2.64C. The propranolol derivative (S)-1ainduced nearly complete irreversible blockage of the β2ARH2.64Cwithin 30 min incubation. The CGP20712A-based ligand(S)-4showed efficient covalent blocking of the β2ARH2.64Cat very low concentrations. The analog(S)-5arevealed extraordinary covalent cross-linking at the β1ARI2.64Cand β2ARH2.64Cmutant while retaining a 41-fold selectivity for the β1AR wild type over β2AR. These compounds may serve as valuable molecular tools for studying β1/β2subtype selectivity or investigations on GPCR trafficking and dimerization.
DOI: 10.1159/000339271
发表时间: 2012-01-01
期刊: CARDIOLOGY
影响因子: 1.9
作者:
Wachter, S. Blake;Gilbert, Edward M.
通讯作者: Gilbert, Edward M.
DOI: 10.1146/annurev.pa.25.040185.001205
发表时间: 1985
影响因子: 12.5
作者:
A. Takemori;P. Portoghese
通讯作者: A. Takemori;P. Portoghese
LK 204-545,一种针对人类 β 肾上腺素受体的高选择性 β1 肾上腺素受体拮抗剂。
DOI: --
发表时间: 1999
影响因子: 5
作者:
S. Louis;T. Nero;D. Iakovidis;G. Jackman;W. Louis
通讯作者: W. Louis
β-肾上腺素受体拮抗剂的体外亲和力和选择性
DOI: --
发表时间: 1985
影响因子: 3
作者:
A. Wellstein;D. Palm;Belz Gg
通讯作者: Belz Gg
DOI: --
发表时间: 1984
影响因子: 7.3
作者:
W. Fuhrer;F. Ostermayer;M. Zimmermann;M. Meier;H. Müller
通讯作者: H. Müller